Clinical trial
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents…
NCT00236041 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00236041 |
|---|---|
| Title | Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP) |
| Official title | A Double-Blind, Placebo-Comparison Study to Evaluate the Efficacy and Safety of ACTIQ® (Oral Transmucosal Fentanyl Citrate [OTFC®]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Breakthrough Pain |
| Intervention type | Drug |
| Interventions | ACTIQ® |
| Enrollment | 38 |
| Start date | Apr 1, 2004 |
| Completion | Aug 1, 2006 |
| First posted | Oct 12, 2005 |
| Last update posted | May 9, 2014 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: